Page 1 | Search Results | ASH Clinical News | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

News

MRD-Guided Treatment Approach Leads to Deep Remissions in CLL

Khylia Marshall

Abstract

View News titled, MRD-Guided Treatment Approach Leads to Deep Remissions in CLL

News

CASSIOPEIA Update: Sustained Benefits With Daratumumab Across Treatment Phases

Khylia Marshall

Abstract

View News titled, CASSIOPEIA Update: Sustained Benefits With Daratumumab Across Treatment Phases

News

Oral Thrombopoietin Receptor Agonist Eltrombopag Also Functions as Iron Chelator, Study Finds

Anna Azvolinsky, PhD

Abstract

View News titled, Oral Thrombopoietin Receptor Agonist Eltrombopag Also Functions as Iron Chelator, Study Finds

News

Itacitinib Prophylaxis Reduces the Incidence of CRS, ICANS in IEC Therapy

Khylia Marshall

Abstract

View News titled, Itacitinib Prophylaxis Reduces the Incidence of CRS, ICANS in IEC Therapy

News

Magrolimab Plus Azacitidine Did Not Improve Outcomes in TP53-Mutated AML

Leah Lawrence

Abstract

View News titled, Magrolimab Plus Azacitidine Did Not Improve Outcomes in TP53-Mutated AML

News

Cyclophosphamide May Mitigate Movement, Neurocognitive Treatment-Emergent Adverse Events Following Cilta-Cel for R/R MM

Katie Robinson

Abstract

View News titled, Cyclophosphamide May Mitigate Movement, Neurocognitive Treatment-Emergent Adverse Events Following Cilta-Cel for R/R MM

News

Analysis Identifies Best MRD Endpoint for Predicting Outcomes in NDMM

Leah Lawrence

Abstract

View News titled, Analysis Identifies Best MRD Endpoint for Predicting Outcomes in NDMM

News

Venetoclax Plus Decitabine Shows Similar Efficacy to Intensive Chemotherapy as Front- Line Therapy for Young, Fit Patients With AML

Anna Azvolinsky, PhD

Abstract

View News titled, Venetoclax Plus Decitabine Shows Similar Efficacy to Intensive Chemotherapy as Front- Line Therapy for Young, Fit Patients With AML

News

Lenalidomide Maintenance Discontinuation a Viable Option for Some Patients With MM

Thomas R. Collins

Abstract

View News titled, Lenalidomide Maintenance Discontinuation a Viable Option for Some Patients With MM

News

PDMPs May Negatively Affect ED Uptake by People With Sickle Cell Disease

Ruth Jessen Hickman, MD

Abstract

View News titled, PDMPs May Negatively Affect ED Uptake by People With Sickle Cell Disease

News

Detailed Analysis of TP53 Status Predicts Transplantation Outcomes in Patients With MDS/AML

Lara C. Pullen, PhD

Abstract

View News titled, Detailed Analysis of TP53 Status Predicts Transplantation Outcomes in Patients With MDS/AML

News

DNMT3A Mutations Found in Frequent Blood Donors, But No Clonal Hematopoiesis Increase

Katie Robinson

Abstract

View News titled, DNMT3A Mutations Found in Frequent Blood Donors, But No Clonal Hematopoiesis Increase

News

Final CAVEAT Results Further Support Venetoclax Plus Intensive Chemotherapy in Older Patients With AML

Leah Lawrence

Abstract

View News titled, Final CAVEAT Results Further Support Venetoclax Plus Intensive Chemotherapy in Older Patients With AML

News

New Tool Aims to Improve Capture of Patient Outcomes in cGVHD-Associated Sclerosis

Thomas R. Collins

Abstract

View News titled, New Tool Aims to Improve Capture of Patient Outcomes in cGVHD-Associated Sclerosis

News

Front-Line Brentuximab Vedotin, Nivolumab Plus Chemotherapy Shows Durable Response, Acceptable Safety in Advanced cHL

Katie Robinson

Abstract

View News titled, Front-Line Brentuximab Vedotin, Nivolumab Plus Chemotherapy Shows Durable Response, Acceptable Safety in Advanced cHL

News

Responses to BCMA CAR T Cells Not Durable in Patients with MM with CNS Involvement

Anna Azvolinsky, PhD

Abstract

View News titled, Responses to BCMA CAR T Cells Not Durable in Patients with MM with CNS Involvement

News

SACRED Trial Shows Utility of Hydroxyurea for Stroke Prevention in Hispanic Children with SCA

Ruth Jessen Hickman, MD

Abstract

View News titled, SACRED Trial Shows Utility of Hydroxyurea for Stroke Prevention in Hispanic Children with SCA

News

BCMA CAR T Cells Effective, Safe for Older Adults and Frail Patients with R/R Multiple Myeloma

Lara C. Pullen, PhD

Abstract

View News titled, BCMA CAR T Cells Effective, Safe for Older Adults and Frail Patients with R/R Multiple Myeloma

News

Mass Spectrometry an Effective Method to Detect Measurable Residual Disease in Multiple Myeloma

Anna Azvolinsky, PhD

Abstract

View News titled, Mass Spectrometry an Effective Method to Detect Measurable Residual Disease in Multiple Myeloma

News

Odronextamab Monotherapy Appears Safe, Effective in R/R DLBCL With Progression After CAR-T

Katie Robinson

Abstract

View News titled, Odronextamab Monotherapy Appears Safe, Effective in R/R DLBCL With Progression After CAR-T

Update search

NARROW

Publications

Format

Topics

Date

Availability

MRD-Guided Treatment Approach Leads to Deep Remissions in CLL

CASSIOPEIA Update: Sustained Benefits With Daratumumab Across Treatment Phases

Oral Thrombopoietin Receptor Agonist Eltrombopag Also Functions as Iron Chelator, Study Finds

Itacitinib Prophylaxis Reduces the Incidence of CRS, ICANS in IEC Therapy

Magrolimab Plus Azacitidine Did Not Improve Outcomes in TP53-Mutated AML

Cyclophosphamide May Mitigate Movement, Neurocognitive Treatment-Emergent Adverse Events Following Cilta-Cel for R/R MM

Analysis Identifies Best MRD Endpoint for Predicting Outcomes in NDMM

Venetoclax Plus Decitabine Shows Similar Efficacy to Intensive Chemotherapy as Front- Line Therapy for Young, Fit Patients With AML

Lenalidomide Maintenance Discontinuation a Viable Option for Some Patients With MM

PDMPs May Negatively Affect ED Uptake by People With Sickle Cell Disease

Detailed Analysis of TP53 Status Predicts Transplantation Outcomes in Patients With MDS/AML

DNMT3A Mutations Found in Frequent Blood Donors, But No Clonal Hematopoiesis Increase

Final CAVEAT Results Further Support Venetoclax Plus Intensive Chemotherapy in Older Patients With AML

New Tool Aims to Improve Capture of Patient Outcomes in cGVHD-Associated Sclerosis

Front-Line Brentuximab Vedotin, Nivolumab Plus Chemotherapy Shows Durable Response, Acceptable Safety in Advanced cHL

Responses to BCMA CAR T Cells Not Durable in Patients with MM with CNS Involvement

SACRED Trial Shows Utility of Hydroxyurea for Stroke Prevention in Hispanic Children with SCA

BCMA CAR T Cells Effective, Safe for Older Adults and Frail Patients with R/R Multiple Myeloma

Mass Spectrometry an Effective Method to Detect Measurable Residual Disease in Multiple Myeloma

Odronextamab Monotherapy Appears Safe, Effective in R/R DLBCL With Progression After CAR-T

ASH Publications

American Society of Hematology

Update search

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only